Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.
Håvard FretheimBrian K ChungHenriette DidriksenEspen S BækkevoldØyvind MidtvedtCathrine BrunborgKristian HolmJørgen ValeurAnders Heiervang TennøeTorhild GarenTore MidtvedtMarius TrøseidHasse ZarèMay Brit LundJohannes R HovProf Knut E A LundinØyvind MolbergAnna-Maria Hoffmann-VoldPublished in: PloS one (2020)
FMT of commercially-available ACHIM is associated with gastroduodenoscopy complications but reduces lower GI symptoms by possibly altering the gut microbiota in patients with SSc.
Keyphrases
- systemic sclerosis
- placebo controlled
- double blind
- interstitial lung disease
- phase iii
- phase ii
- clinical trial
- study protocol
- phase ii study
- risk factors
- cell therapy
- open label
- stem cells
- randomized controlled trial
- squamous cell carcinoma
- radiation therapy
- bone marrow
- mesenchymal stem cells
- physical activity
- locally advanced